CoChat

Role of PD‐L1 Expression in Non‐Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers

Open access
Pawelczyk, Konrad, Piotrowska, Aleksandra, Ciesielska, Urszula, Jablonska, Karolina, Glatzel-Plucinska, Natalia, Grzegrzolka, Jedrzej, Podhorska-Okolow, Marzenna, Dziegiel, Piotr, Nowinska, Katarzyna · 2019 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.

Abstract

Background: The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The association between PD-L1 expression and clinicopathological features is still unclear. Therefore, we examined this relationship and also compare PD-L1 expression levels with Ki-67, p63 and TTF-1. Methods: 866 samples of NSCLCs were used to prepare tissue microarrays (TMAs) on which immunohistochemical (IHC) reactions were performed. Changes in the level of CD274 (PD-L1) gene expression in 62 NSCLC tumors were tested in relation to 14 normal lung tissues by real-time PCR reactions (RT-PCR). Results: PD-L1 expression was observed in 32.6% of NSCLCs. PD-L1 expression was increased in higher malignancy grades (G) (p < 0.0001) and in higher lymph node status (pN) (p = 0.0428). The patients with low PD-L1 expression had longer overall survival compared to the group with high expression (p = 0.0332) in adenocarcinoma (AC) only. Conclusions: PD-L1 expression seems to be associated with increased tumor proliferation and aggressiveness as well as shorter patient survival in NSCLC, predominantly in the AC group.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms20040824

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Positive membranous immunohistochemical reaction (brown) indicating PD-L1 expression performed on healthy lung tissue (A,B) and in different grades of malignancy in adenocarcinoma (AC) (C,E,G) and squamous cell cancer (SCC) (D,F,H). Lack of PD-L1 expression—healthy lung tissue (A) and PD-L1 expression in macrophages—positive control (B). Expression of PD-L1 increased in higher malignancy grade in AC—G1 (C), G2 (E), and G3 (G), and in SCC—G1 (D), G2 (F) and G3 (H), magnification, ×200.
Figure 1 Positive membranous immunohistochemical reaction (brown) indicating PD-L1 expression performed on healthy lung tissue (A,B) and in different grades of malignancy in adenocarcinoma (AC) (C,E,G) and squamous cell cancer (SCC) (D,F,H). Lack of PD-L1 expression—healthy lung tissue (A) and PD-L1 expression in macrophages—positive control (B). Expression of PD-L1 increased in higher malignancy grade in AC—G1 (C), G2 (E), and G3 (G), and in SCC—G1 (D), G2 (F) and G3 (H), magnification, ×200.CC BY · PubMed Central
Figure 2 PD-L1 protein expression and CD274 mRNA in non-small cell lung cancer (NSCLC) are higher than in healthy lung tissues. Comparison of PD-L1 protein expression levels detected by immunohistochemistry (IHC) (A) in different subtypes of NSCLC (* p = 0.0074). Positive correlation between mRNA expression levels of CD274 detected by the real-time PCR and PD-L1 expression detected by IHC evaluated by Tumor Proportion Score (TPS (0–2) (B). Comparison between expression of mRNA CD274 in healthy lung tissues and NSCLC (C) adenocarcinoma (AC) (D) squamous cell cancer (SCC) (E).
Figure 2 PD-L1 protein expression and CD274 mRNA in non-small cell lung cancer (NSCLC) are higher than in healthy lung tissues. Comparison of PD-L1 protein expression levels detected by immunohistochemistry (IHC) (A) in different subtypes of NSCLC (* p = 0.0074). Positive correlation between mRNA expression levels of CD274 detected by the real-time PCR and PD-L1 expression detected by IHC evaluated by Tumor Proportion Score (TPS (0–2) (B). Comparison between expression of mRNA CD274 in healthy lung tissues and NSCLC (C) adenocarcinoma (AC) (D) squamous cell cancer (SCC) (E).CC BY · PubMed Central
Figure 3 The higher the grade (G) of malignancy, the higher the PD-L1 expression observed. Comparison of PD-L1 protein expression levels in different grades of malignancy (G) of non-small cell lung cancer (NSCLC) (A), adenocarcinoma (AC) (B), squamous cell cancer (SCC) (C) * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
Figure 3 The higher the grade (G) of malignancy, the higher the PD-L1 expression observed. Comparison of PD-L1 protein expression levels in different grades of malignancy (G) of non-small cell lung cancer (NSCLC) (A), adenocarcinoma (AC) (B), squamous cell cancer (SCC) (C) * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.CC BY · PubMed Central
Figure 4 Patients with low PD-L1 expression (0–1 point) had longer survival compared to the group with high expression (2 points) (p = 0.0229) in AC subtype. Comparison of Kaplan-Meier curves presenting overall survival percentage in patients with NSCLC (A), AC (B), SCC (C) according to low (0–1) and high (2) levels of PD-L1 expression.
Figure 4 Patients with low PD-L1 expression (0–1 point) had longer survival compared to the group with high expression (2 points) (p = 0.0229) in AC subtype. Comparison of Kaplan-Meier curves presenting overall survival percentage in patients with NSCLC (A), AC (B), SCC (C) according to low (0–1) and high (2) levels of PD-L1 expression.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 192

Metadata

Authors
Pawelczyk, K., Piotrowska, A., Ciesielska, U., Jablonska, K., Glatzel-Plucinska, N., Grzegrzolka, J., Podhorska-Okolow, M., Dziegiel, P., & Nowinska, K.
Affiliations
  • Department of Thoracic Surgery, Wroclaw Medical University, Wroclaw 53-439, Poland
  • Wroclaw Medical University (PL)
  • Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw 50-368, Poland
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2019-02-14
Volume
20
Issue
4
Pages
824
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2913496992
Cited by
192
References
50
Citations by year
2026: 8 · 2025: 16 · 2024: 39 · 2023: 29 · 2022: 35 · 2021: 37 · 2020: 22 · 2019: 6
FWCI
10.43
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu (ST.A110.17.037)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
PD-L1, non-small cell lung cancer, prognostic factors, tumor grade, lymph node metastasis, overall survival, lung adenocarcinoma, Ki-67, p63, TTF-1, PD-1/PD-L1 immune checkpoint, tumor cell proliferation
MeSH terms
Thyroid Nuclear Factor 1, Adenocarcinoma, Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Male, Membrane Proteins, Middle Aged, Prognosis, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Ki-67 Antigen, Tissue Array Analysis, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.